Novel Dry Powder Inhaler particle-dispersion Systems

• Smyth HD . The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv. Drug Deliv. Rev.55(7), 807–828 (2003).
   PubMed Web of Science ®Google Scholar
• Smyth HD , LeachCL. Alternative propellant aerosol delivery systems. Crit. Rev. Ther. Drug Carrier Syst.22(6), 493–534 (2005).
   PubMed Web of Science ®Google Scholar
• Newman S , ClarkeS. Therapeutic aerosols 1 – physical and practical considerations. Thorax38(12), 881 (1983).
   PubMed Web of Science ®Google Scholar
• Byron P . Some future perspectives for unit dose inhalation aerosols. Drug Dev. Ind. Pharm.12(7), 993–1015 (1986).
   Web of Science ®Google Scholar
• Krupp H . Particle adhesion, theory and experiment. Advan. Colloid Interface Sci.1, 111–239, (1967).
   Google Scholar
• Finlay WH . The Mechanics of Inhaled Pharmaceutical Aerosols: an Introduction. Academic Press, Waltham, MA, USA (2001).
   Google Scholar
• Butt HJ , KapplM. Surface and Interfacial Forces. Wiley-VCH, Weinheim, Germany (2010).
   Google Scholar
• Cassidy OE , CarterPA, RowleyG, MerrifieldDR. Triboelectrification of spray dried lactose prepared from different feedstock concentrations. J. Pharm. Pharmacol.52(1), 13–17 (2000).
   PubMed Web of Science ®Google Scholar
• Hertz H . Ueber die Berührung fester elastischer Körper. Journal für die reine und angewandte Mathematik (Crelles Journal)1882(92), 156–171 (2011).
   Google Scholar
• Derjaguin B . Untersuchungen ueber die reibung und adhaesion, IV. Kolloid-Zeitschrift69(2), 155–164 (1934).
   Google Scholar
• Johnson K , KendallK, RobertsA. Surface energy and the contact of elastic solids. Proc. Royal Soc. London. A. Math. Phys. Sci.324(1558), 301 (1971).
   Web of Science ®Google Scholar
• Derjaguin B , MullerV, ToporovYP. Effect of contact deformations on the adhesion of particles. J. Colloid Interface Sci.53(2), 314–326 (1975).
   Web of Science ®Google Scholar
• Maugis D . Adhesion of spheres: the JKR-DMT transition using a Dugdale model. J. Colloid Interface Sci.150(1), 243–269 (1992).
   Web of Science ®Google Scholar
• Rabinovich YI , AdlerJJ, AtaA, SinghRK, MoudgilBM. Adhesion between nanoscale rough surfaces: I. Role of asperity geometry. J. Colloid Interface Sci.232(1), 10–16 (2000).
   PubMed Web of Science ®Google Scholar
• Rabinovich YI , AdlerJJ, AtaA, SinghRK, MoudgilBM. Adhesion between nanoscale rough surfaces: II. Measurement and comparison with theory. J. Colloid Interface Sci.232(1), 17–24 (2000).
   PubMed Web of Science ®Google Scholar
• Dunbar C , HickeyA, HolznerP. Dispersion and characterization of pharmaceutical dry-powder aerosols. Kona16, 7–45 (1998).
   Google Scholar
• Podczeck F , NewtonJM. Development of an ultracentrifuge technique to determine the adhesion and friction properties between particles and surfaces. J. Pharm. Sci.84(9), 1067–1071 (1995).
   PubMed Web of Science ®Google Scholar
• Podczeck F , NewtonJ, JamesM. The adhesion force of micronized Salmeterol Xinafoate particles to pharmaceutically relevant surface materials. J. Phys. D Appl. Phys.29, 1878 (1996).
   Web of Science ®Google Scholar
• Podczeck F , NewtonJM, JamesMB. Assessment of adhesion and autoadhesion forces between particles and surfaces. J. Adhesion Sci. Technol.8(12), 1459–1472 (1994).
   Web of Science ®Google Scholar
• Podczeck F , NewtonJM, JamesMB. Influence of relative humidity of storage air on the adhesion and autoadhesion of micronized particles to particulate and compacted powder surfaces 1. J. Colloid Interface Sci.187(2), 484–491 (1997).
   PubMed Web of Science ®Google Scholar
• Podczeck F . The relationship between particulate properties of carrier materials and the adhesion force of drug particles in interactive powder mixtures. J. Adhesion Sci. Technol.11(8), 1089–1104 (1997).
   Web of Science ®Google Scholar
• Podczeck F . Assessment of the mode of adherence and the deformation characteristics of micronized particles adhering to various surfaces. Int. J. Pharm.145(1–2), 65–76 (1996).
   Web of Science ®Google Scholar
• Selvam P , MarekS, TrumanCR, McnairD, SmythHDC. Micronized drug adhesion and detachment from surfaces: effect of loading conditions. Aerosol Sci. Technol.45(1), 81–87 (2011).
   Web of Science ®Google Scholar
• Louey MD , MulvaneyP, StewartPJ. Characterisation of adhesional properties of lactose carriers using atomic force microscopy. J. Pharm. Biomed. Anal.25(3–4), 559–567 (2001).
   PubMed Web of Science ®Google Scholar
• Hooton JC , JonesMD, HarrisH, ShurJ, PriceR. The influence of crystal habit on the prediction of dry powder inhalation formulation performance using the cohesive–adhesive force balance approach. Drug Devel. Ind. Pharm.34(9), 974–983 (2008).
   PubMed Web of Science ®Google Scholar
• Hooton JC , JonesMD, PriceR. Predicting the behavior of novel sugar carriers for dry powder inhaler formulations via the use of a cohesive–adhesive force balance approach. J. Pharm. Sci.95(6), 1288–1297 (2006).
   PubMed Web of Science ®Google Scholar
• Begat P , Morton DaV, Staniforth JN, Price R. The cohesive–adhesive balances in dry powder inhaler formulations I: direct quantification by atomic force microscopy. Pharm. Res.21(9), 1591–1597 (2004).
   PubMed Web of Science ®Google Scholar
• De Boer A , HagedoornP, GjaltemaD, GoedeJ, FrijlinkH. Air classifier technology (ACT) in dry powder inhalation: part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. Int. J. Pharm.260(2), 187–200 (2003).
   PubMedGoogle Scholar
• Nichols S , WynnE. New Approaches to Optimising Dispersion in Dry Powder Inhaler-dispersion Force Mapping and Adhesion Measurements. DHI Publishing, River Grove, IL, USA (2008).
   Google Scholar
• Selvam P , McnairD, TrumanR, SmythHDC. A novel dry powder inhaler: effect of device design on dispersion performance. Int. J. Pharm. (2010).
   PubMedGoogle Scholar
• Marek SR , DonovanMJ, SmythHDC. Effects of mild processing pressures on the performance of dry powder inhaler formulations for inhalation therapy (1): budesonide and lactose. Eur. J. Pharm. Biopharm.78(1), 97–106 (2010).
   PubMed Web of Science ®Google Scholar
• Frijlink HW , De Boer AH. Trends in the technology-driven development of new inhalation devices. Drug Discov. Today Technol.2(1), 47–57 (2005).
   PubMedGoogle Scholar
• Coates MS , ChanHK, FletcherDF, RaperJA. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm. Res.22(9), 1445–1453 (2005).
   PubMed Web of Science ®Google Scholar
• Chew NY , ChanHK. In vitro aerosol performance and dose uniformity between the foradile aerolizer and the oxis Turbuhaler. J. Aerosol Med.14(4), 495–501 (2001).
   PubMedGoogle Scholar
• Weuthen T , RoederS, BrandP, MullingerB, ScheuchG. In vitro testing of two formoterol dry powder inhalers at different flow rates. J. Aerosol Med.15(3), 297–303 (2002).
   PubMedGoogle Scholar
• Pilcer G , WauthozN, AmighiK. Lactose characteristics and the generation of the aerosol. Adv. Drug Deliv. Rev. (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Kamin WE , GenzT, RoederSet al. Mass output and particle size distribution of glucocorticosteroids emitted from different inhalation devices depending on various inspiratory parameters. J. Aerosol Med. 15(1), 65–73 (2002).
   PubMedGoogle Scholar
• Palander A , MattilaT, KarhuM, MuttonenE. In vitro comparison of three salbutamol-containing multidose dry powder inhalers: Buventol Easyhaler, Inspiryl Turbuhaler and Ventoline Diskus. Clin. Drug Invest.20(1), 25–33 (2000).
   Web of Science ®Google Scholar
• Chodosh S , FlandersJS, KestenS, SerbyCW, HochrainerD, WitekTJ Jr. Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity. J. Aerosol Med.14(3), 309–315 (2001).
   PubMedGoogle Scholar
• Smith KJ , ChanHK, BrownKF. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers. J. Aerosol Med.11(4), 231–245 (1998).
   PubMedGoogle Scholar
• Dehaan W , FinlayW. Predicting extrathoracic deposition from dry powder inhalers. J. Aerosol Sci.35(3), 309–331 (2004).
   Web of Science ®Google Scholar
• Coates MS , ChanHK, FletcherDF, ChiouH. Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler. Pharm. Res.24(8), 1450–1456 (2007).
   PubMed Web of Science ®Google Scholar
• Gupta V , GuptaSK. Fluid Mechanics and its Applications. Wiley Eastern, New Delhi, India (1984).
   Google Scholar
• Coates MS , FletcherDF, ChanHK, RaperJA. The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses. Pharm. Res.22(6), 923–932 (2005).
   PubMed Web of Science ®Google Scholar
• Bell J , HartleyP, CoxJ. Dry powder aerosols I: a new powder inhalation device. J. Pharm. Sci.60(10), 1559–1564 (1971).
   PubMed Web of Science ®Google Scholar
• Newman SP , BusseWW. Evolution of dry powder inhaler design, formulation, and performance. Respir. Med.96(5), 293–304 (2002).
   PubMed Web of Science ®Google Scholar
• Borgstrom L . Deposition patterns with Turbuhaler. J. Aerosol Med.7(Suppl. 1), S49–S53 (1994).
   PubMedGoogle Scholar
• Auty RM , BrownK, NealeMG, SnashallPD. Respiratory tract deposition of sodium cromoglycate is highly dependent upon technique of inhalation using the Spinhaler. Br. J. Dis. Chest81, 371–380 (1987).
   PubMedGoogle Scholar
• Islam N , GladkiE. Dry powder inhalers (DPIs) – a review of device reliability and innovation. Int. J. Pharm.360(1–2), 1–11 (2008).
   PubMed Web of Science ®Google Scholar
• Prime D , AtkinsPJ, SlaterA, SumbyB. Review of dry powder inhalers. Adv. Drug Deliv. Rev.26(1), 51–58 (1997).
   PubMed Web of Science ®Google Scholar
• Wetterlin K . Turbuhaler: a new powder inhaler for administration of drugs to the airways. Pharm. Res.5(8), 506–508 (1988).
   PubMed Web of Science ®Google Scholar
• Smith IJ , Parry-BillingsM. The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther.16(2), 79–95 (2003).
   PubMed Web of Science ®Google Scholar
• Steckel H , MullerBW. In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devices. 154(1), 19–29 (1997).
   Google Scholar
• Lamb E . Top 200 drugs of 2008. Pharmacy Times5, 26–28 (2009).
   Google Scholar
• Muchmore DB , SilvermanB, PeñaADL, TobianJ. The AIR® inhaled insulin system: system components and pharmacokinetic/glucodynamic data. Diabetes Technol. Ther.9(Suppl. 1), 41–47 (2007).
   PubMed Web of Science ®Google Scholar
• Delong M , WrightJ, DawsonM, MeyerT, SommererK, DunbarC. Dose delivery characteristics of the AIR® pulmonary delivery system over a range of inspiratory flow rates. J. Aerosol Med.18(4), 452–459 (2005).
   PubMedGoogle Scholar
• Vehring R . Pharmaceutical particle engineering via spray drying. Pharm. Res.25(5), 999–1022 (2008).
   PubMed Web of Science ®Google Scholar
• Weers JG , TararaTE, ClarkAR. Design of fine particles for pulmonary drug delivery. Expert Opin. Drug Deliv.4(3), 297–313 (2007).
   PubMed Web of Science ®Google Scholar
• Brambilla G , CocconiD, ArmanniA, SmithS, LyeE, BurgeS. Designing a novel dry powder inhaler: the NEXT™ DPI (part 1). Resp. Drug Deliv.2, 553–555 (2006).
   Google Scholar
• Needham M , FradleyG, CocksP. Investigating the efficiency of reverse cyclone technology for DPI drug delivery. Resp. Drug Deliv.2, 369–372 (2010).
   Google Scholar
• Smith IJ , Parry-BillingsM. The inhalers of the future? A review of dry powder devices on the market today. Pulm. Pharmacol. Ther.16(2), 79–95 (2003).
   PubMed Web of Science ®Google Scholar
• Bisgaard H , KlugB, SumbyB, BurnellP. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur. Resp. J.11(5), 1111 (1998).
   PubMed Web of Science ®Google Scholar
• Watling C , ElliottJ, CameronR. Entrainment of lactose inhalation powders: a study using laser diffraction. Eur. J. Pharm. Sci.40(4), 352–358 (2010).
   PubMed Web of Science ®Google Scholar
• De Boer AH , HagedoornP, GjaltemaD, GoedeJ, FrijlinkHW. Air classifier technology (ACT) in dry powder inhalation. Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures. Int. J. Pharm.260(2), 187–200 (2003).
   PubMedGoogle Scholar
• De Boer A , HagedoornP, GjaltemaD, GoedeJ, FrijlinkH. Air classifier technology (ACT) in dry powder inhalation: part 3. Design and development of an air classifier family for the Novolizer® multi-dose dry powder inhaler. Int. J. Pharm.310(1–2), 72–80 (2006).
   PubMed Web of Science ®Google Scholar
• De Boer A , HagedoornP, GjaltemaD, GoedeJ, FrijlinkH. Air classifier technology (ACT) in dry powder inhalation: part 4. Performance of air classifier technology in the Novolizer® multi-dose dry powder inhaler. Int. J. Pharm.310(1–2), 81–89 (2006).
   PubMed Web of Science ®Google Scholar
• Munzel U , MarschallK, FyrnysB, WedelM. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers. Curr. Med. Res. Opin.21(6), 827–833 (2005).
   PubMed Web of Science ®Google Scholar
• Gardner D , CasperB. Development of the Acu-Breath™ dry powder inhaler. Drug Deliv. Technol.5(4), 30–39 (2005).
   Google Scholar
• Donovan M , SmythHDC. Widening the lens: re-evaluating the influence of size and morphology of DPI carrier particle performance. Drug Deliv. Lung43–46 (2011).
   Google Scholar
• Steckel H , MullerBW. In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devices. Int. J. Pharm.154(1), 19–29 (1997).
   Web of Science ®Google Scholar
• Srichana T , MartinG, MarriottC. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur. J. Pharm. Sci.7(1), 73–80 (1998).
   PubMed Web of Science ®Google Scholar
• De Boer A , GjaltemaD, HagedoornP. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers part 2: effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int. J. Pharm.138(1), 45–56 (1996).
   Google Scholar
• Ganderton D , KassemNM. Dry powder inhalers. Adv. Pharm. Sci.6, 165–191 (1992).
   Google Scholar
• Zeng XM , MartinGP, TeeSK, MarriottC. The role of fine particle lactose on the dispersion and deaggregation of salbutamol sulphate in an air stream in vitro. Int. J. Pharm.176(1), 99–110 (1998).
   Web of Science ®Google Scholar
• Lucas P , AndersonK, StaniforthJN. Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers. Pharm. Res.15(4), 562–569 (1998).
   PubMed Web of Science ®Google Scholar
• Son YJ , McconvilleJT. Advancements in dry powder delivery to the lung. Drug Dev. Ind. Pharm.34(9), 948–959 (2008).
   PubMed Web of Science ®Google Scholar
• Hickey AJ . Next Generation Dry Powder Inhalation Delivery Systems. Informa Healthcare USA Inc., NY, USA. 445–460 (2007).
   Google Scholar
• Weers JG , BellJ, ChanHKet al. Pulmonary formulations: what remains to be done? J. Aerosol Med. Pulm. Drug Deliv. 23(S2), 5–23 (2010).
   PubMed Web of Science ®Google Scholar
• Tiddens HA , GellerDE, ChallonerPet al. Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older. J. Aerosol Med. 19(4), 456–465 (2006).
   PubMedGoogle Scholar
• Clark A , HollingworthA. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers – implications for in vitro testing. J. Aerosol Med.6(2), 99–110 (1993).
   PubMedGoogle Scholar
• Agertoft L , PedersenS, NikanderK. Drug delivery from the Turbuhaler and Nebuhaler pressurized metered dose inhaler to various age groups of children with asthma. J. Aerosol Med.12(3), 161–169 (1999).
   PubMedGoogle Scholar
• Schultz R , MillerN, SmithD, RossD. Powder aerosols with auxiliary means of dispersion. J. Biopharm. Sci3, 115–121 (1992).
   Google Scholar
• Hill M . Characteristics of an active multiple dose dry powder inhaler. Resp. Drug Deliv.109, 116 (1994).
   Google Scholar
• Crowder TM . 2001: an odyssey in inhaler formulation and design. Pharm. Technol.25(7), 99–113 (2001).
   Google Scholar
• Tobyn M , StaniforthJN, MortonD, HarmerQ, NewtonME. Active and intelligent inhaler device development. Int. J. Pharm.277(1–2), 31–37 (2004).
   PubMedGoogle Scholar
• White S , BennettDB, CheuSet al. EXUBERA®: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol. Ther. 7(6), 896–906 (2005).
   PubMedGoogle Scholar
• Harper NJ , GrayS, GrootJDet al. The design and performance of the Exubera® pulmonary insulin delivery system. Diabetes Technol. Ther. 9(S1), 16–27 (2007).
   PubMed Web of Science ®Google Scholar
• Mack GS . Pfizer dumps Exubera. Nat. Biotechnol.25(12), 1331–1332 (2007).
   PubMed Web of Science ®Google Scholar
• Weintraub A . Pfizer‘s Exubera flop. BusinessWeek: Technology, 18 October 2007.
   Google Scholar
• Grosset KA . Inhaled apomorphine (VR040) for “off” periods in Parkinson‘s disease. Presented at: The Movement Disorder Society‘s 15th International Congress of Parkinson‘s Disease and Movement Disorders. Toronto, ON, Canada, 5–9 June 2011.
   Google Scholar
• Keating GM , FauldsD. Airmax: a multi-dose dry powder inhaler. Drugs62(13), 1887–1895 (2002).
   PubMed Web of Science ®Google Scholar
• Zeng XM , O‘LearyD, PhelanM, JonesS, ColledgeJ. Delivery of salbutamol and of budesonide from a novel multi-dose inhaler Airmax™. Respir. Med.96(6), 404–411 (2002).
   PubMed Web of Science ®Google Scholar
• Nelson H , KempJP, BielerS, VaughanLM, HillMR. Comparative efficacy and safety of albuterol sulfate Spiros inhaler and albuterol metered-dose inhaler in asthma. Chest115(2), 329–335 (1999).
   PubMed Web of Science ®Google Scholar
• Ahrens RC , HendelesL, ClarkeWRet al. Therapeutic equivalence of Spiros dry powder inhaler and Ventolin metered dose inhaler. A bioassay using methacholine. Am. J. Respir. Crit. Care Med. 160(4), 1238–1243 (1999).
   PubMed Web of Science ®Google Scholar
• Newman S , BusseW. Evolution of dry powder inhaler design, formulation, and performance. Respir. Med.96(5), 293–304 (2002).
   PubMed Web of Science ®Google Scholar
• Schulte M , OsseiranK, BetzRet al. Handling of and preferences for available dry powder inhaler systems by patients with asthma and COPD. J. Aerosol Med. Pulm. Drug Deliv. 21(4), 321–328 (2008).
   PubMed Web of Science ®Google Scholar
• Sitz R . Current innovations in dry powder inhalers. Orally inhaled and nasal drug products: innovations from major delivery system developers. ONdrugDelivery10–12 (2010).
   Google Scholar
• Brown B , RasmussenJ, BeckerD, FriendD. A piezo-electronic inhaler for local & systemic applications. Drug Deliv. Technol.4, 90–93 (2004).
   Google Scholar
• Boekestein VJ , HickeyAJ, CrowderTM. Uniform and reproducible delivery of albuterol from a variety of lactose powder blends using the Oriel active dispersion platform. Drug Deliv. Lungs XIII107–110 (2002).
   Google Scholar
• Geller DE , WeersJ, HeuerdingS. Development of an inhaled dry-powder formulation of tobramycin using Pulmosphere™ technology. J. Aerosol Med. Pulm. Drug Deliv.24(4), 175–185 (2011).
   PubMed Web of Science ®Google Scholar
• Smith IJ , BellJ, BowmanN, EverardM, SteinS, WeersJG. Inhaler devices: what remains to be done? J. Aerosol Med. Pulm. Drug Deliv.23(Suppl. 2), 25–37 (2010).
   PubMed Web of Science ®Google Scholar

Patents

• Jago Research AG: US6182655 (2001).
   Google Scholar
• Oriel Therapeutics Inc.: WO0314619 (2003).
   Google Scholar